Mucormycosis as a complication of COVID-19 coronavirus infection: eye symptoms

COVID-19 causes an immunosuppressive condition and increases the risk of secondary infections, including fungal diseases such as mucormycosis (MM), so doctors should be aware of the possibility of MM development in COVID-19 patients. Since no specific complaints or clinical symptoms exist and the di...

Full description

Saved in:
Bibliographic Details
Main Authors: A. E. Babushkin, L. I. Gilemzianova, I. P. Ponomarev
Format: Article
Language:Russian
Published: Real Time Ltd 2024-07-01
Series:Российский офтальмологический журнал
Subjects:
Online Access:https://roj.igb.ru/jour/article/view/1499
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850047626896998400
author A. E. Babushkin
L. I. Gilemzianova
I. P. Ponomarev
author_facet A. E. Babushkin
L. I. Gilemzianova
I. P. Ponomarev
author_sort A. E. Babushkin
collection DOAJ
description COVID-19 causes an immunosuppressive condition and increases the risk of secondary infections, including fungal diseases such as mucormycosis (MM), so doctors should be aware of the possibility of MM development in COVID-19 patients. Since no specific complaints or clinical symptoms exist and the disease is rare, especially in developed countries with a moderate climate, it is often impossible to diagnose MM at the initial examination. Therefore, the detection of the pathogen (mycelium zygomycetes) plays a key role in the diagnosis. Over 70 % of MM patients experience eye damages. According to the literature, the most common manifestations thereof are blepharoptosis, ophthalmoplegia, exophthalmos, injection and conjunctival chemosis. Quite often, the patients have eye pains, orbital cellulitis or phlegmon of the orbit, accompanied by a decrease in vision. For the effective treatment of this severe infectious COVID-19 complication, which takes the form of deep and aggressive mycosis, an interdisciplinary approach is necessary. The complex treatment should make use of antimycotic agents and symptomatic therapy, and, essentially, surgical rehabilitation of infection foci by removing the affected necrotic tissues. The prognosis is always very serious.
format Article
id doaj-art-1d7678bd1d924f3aaba638e9f68b85ac
institution DOAJ
issn 2072-0076
2587-5760
language Russian
publishDate 2024-07-01
publisher Real Time Ltd
record_format Article
series Российский офтальмологический журнал
spelling doaj-art-1d7678bd1d924f3aaba638e9f68b85ac2025-08-20T02:54:11ZrusReal Time LtdРоссийский офтальмологический журнал2072-00762587-57602024-07-0117211612010.21516/2072-0076-2024-17-2-116-120696Mucormycosis as a complication of COVID-19 coronavirus infection: eye symptomsA. E. Babushkin0L. I. Gilemzianova1I. P. Ponomarev2Ufa Eye Research Institute, Bashkir Medical UniversityUfa Eye Research Institute, Bashkir Medical UniversityUfa Eye Research Institute, Bashkir Medical UniversityCOVID-19 causes an immunosuppressive condition and increases the risk of secondary infections, including fungal diseases such as mucormycosis (MM), so doctors should be aware of the possibility of MM development in COVID-19 patients. Since no specific complaints or clinical symptoms exist and the disease is rare, especially in developed countries with a moderate climate, it is often impossible to diagnose MM at the initial examination. Therefore, the detection of the pathogen (mycelium zygomycetes) plays a key role in the diagnosis. Over 70 % of MM patients experience eye damages. According to the literature, the most common manifestations thereof are blepharoptosis, ophthalmoplegia, exophthalmos, injection and conjunctival chemosis. Quite often, the patients have eye pains, orbital cellulitis or phlegmon of the orbit, accompanied by a decrease in vision. For the effective treatment of this severe infectious COVID-19 complication, which takes the form of deep and aggressive mycosis, an interdisciplinary approach is necessary. The complex treatment should make use of antimycotic agents and symptomatic therapy, and, essentially, surgical rehabilitation of infection foci by removing the affected necrotic tissues. The prognosis is always very serious.https://roj.igb.ru/jour/article/view/1499coronavirus infectioncovid-19complicationimmunosuppressive staterisk of secondary infectionsmucormycosiseye damage
spellingShingle A. E. Babushkin
L. I. Gilemzianova
I. P. Ponomarev
Mucormycosis as a complication of COVID-19 coronavirus infection: eye symptoms
Российский офтальмологический журнал
coronavirus infection
covid-19
complication
immunosuppressive state
risk of secondary infections
mucormycosis
eye damage
title Mucormycosis as a complication of COVID-19 coronavirus infection: eye symptoms
title_full Mucormycosis as a complication of COVID-19 coronavirus infection: eye symptoms
title_fullStr Mucormycosis as a complication of COVID-19 coronavirus infection: eye symptoms
title_full_unstemmed Mucormycosis as a complication of COVID-19 coronavirus infection: eye symptoms
title_short Mucormycosis as a complication of COVID-19 coronavirus infection: eye symptoms
title_sort mucormycosis as a complication of covid 19 coronavirus infection eye symptoms
topic coronavirus infection
covid-19
complication
immunosuppressive state
risk of secondary infections
mucormycosis
eye damage
url https://roj.igb.ru/jour/article/view/1499
work_keys_str_mv AT aebabushkin mucormycosisasacomplicationofcovid19coronavirusinfectioneyesymptoms
AT ligilemzianova mucormycosisasacomplicationofcovid19coronavirusinfectioneyesymptoms
AT ipponomarev mucormycosisasacomplicationofcovid19coronavirusinfectioneyesymptoms